cas 5580-80-3|| where to buy 2,3,4,5-Tetrafluoroaniline

Product Name:2,3,4,5-Tetrafluoroaniline

IUPAC Name:2,3,4,5-tetrafluoroaniline

Packing Unit	Available Stock	Price($)
CM118575-10g	in stock	țƎ
CM118575-25g	in stock	ũȬȺ
CM118575-100g	in stock	ƦțȺ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:5580-80-3; Molecular Formula:C6H3F4N; Melting Point:-; Smiles Code:NC1=CC(F)=C(F)C(F)=C1F; Density:

: Catalog Number:CM118575; Molecular Weight:165.09; Boiling Point:191°C at 760 mmHg; MDL No:MFCD00025153; Storage:Keep in dark place, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Glecirasib; On January 20, Jacobio Pharma presents data of glecirasib in patients with pancreatic cancer and other solid tumors at the 2024 ASCO GI. For second-line and above KRAS G12C mutated pancreatic cancer patients, the confirmed objective response rate (cORR) was 41.9% and the disease control rate (DCR) was 93.5%. Glecirasib is a potential best-in-class KRAS G12C allosteric inhibitor with promising early clinical efficacy. Glecirasib can be used as monotherapy to treat non-small cell lung cancer, colorectal cancer and other solid tumors with the KRAS G12C mutation. Combinations of Glecirasib with SHP2i, EGFRi, or PD-1 antibodies is expected to have synergistic efficacy and overcome acquired drug resistance.